Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Proteomic Analysis of Serum of Women with Elevated Ca-125 to Differentiate Malignant from Benign Ovarian Tumors

  • Li, Li (Department of Gynecology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Xu, Yi (Department of Gynecology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Yu, Chun-Xia (Department of Gynecology, Affiliated Tumor Hospital, Xinjiang Medical University)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Clinically, elevated cancer antigen 125 (CA-125) in blood predicts tumor burden in a woman's body, especially in the ovary, but cannot differentiate between malignant or benign. We here used intensive modern proteomic approaches to identify predictive proteins in the serum of women with elevated CA-125 to differentiate malignant from benign ovarian tumors. We identified differentially expressed proteins in serum samples of ovarian cancer (OC) patients, benign ovarian tumor (BT) patients, and healthy control women using mass spectrometry-based quantitative proteomics. Both the OC and BT patients had elevated CA-125. Quantitation was achieved using isobaric tags for relative and absolute quantitation. We obtained 124 quantified differential serum proteins in OC compared with BT. Two proteins, apolipoprotein A-4 (APOA4) and natural resistance-associated macrophage 1, were verified using Western blotting. Proteome profiling applied to OC cases identified several differential serum proteins in the serum of women with elevated CA-125. A novel protein, APOA4, has the potential to be a marker for malignant tumor differentiation in the serum of women with elevated CA-125.

Keywords

References

  1. Alzheimer's Association (2009). Cancer Facts and Figures 2009 US. Alzheimers Dement, 5, 234-70. https://doi.org/10.1016/j.jalz.2009.03.001
  2. Amon LM, Law W, Fitzgibbon MP, et al (2010). Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PLoS One, 5, e11137. https://doi.org/10.1371/journal.pone.0011137
  3. Awomoyi AA (2007). The human solute carrier family 11 member 1 protein (SLC11A1): linking infections, autoimmunity and cancer? FEMS Immunol Med Microbiol, 49, 324-9. https://doi.org/10.1111/j.1574-695X.2007.00231.x
  4. Bagan P, Berna P, Assouad J, et al (2008). Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax. Eur Respir J, 31, 140-2. https://doi.org/10.1183/09031936.00094206
  5. Bast RC Jr, Xu FJ, Yu YH, et al (1998). CA 125: the past and the future. Int J Biol Markers, 13, 179-87.
  6. Beisiegel U, Utermann G (1979). An apolipoprotein homolog of rat apolipoprotein A-IV in human plasma. Isolation and partial characterisation. Eur J Biochem, 93, 601-8. https://doi.org/10.1111/j.1432-1033.1979.tb12860.x
  7. DeSouza L, Diehl G, Rodrigues MJ, et al (2005). Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res, 4, 377-86. https://doi.org/10.1021/pr049821j
  8. Dieplinger H, Ankerst DP, Burges A, et al (2009). Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev, 18, 1127-33. https://doi.org/10.1158/1055-9965.EPI-08-0653
  9. Gao LL, Li FR, Jiao P, et al (2011). Apoptosis of human ovarian cancer cells induced by Paris chinensis dioscin via a Ca(2+)-mediated mitochondrion pathway. Asian Pac J Cancer Prev, 12, 1361-6.
  10. Goswami T, Bhattacharjee A, Babal P, et al (2001). Natural-resistance-associated macrophage protein 1 is an H+/bivalent cation antiporter. Biochem J, 354, 511-9. https://doi.org/10.1042/0264-6021:3540511
  11. Huang da W, Sherman BT, Lempicki RA (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4, 44-57.
  12. Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002). Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem, 74, 5383-92. https://doi.org/10.1021/ac025747h
  13. Lai CQ, Parnell LD, Ordovas JM (2005). The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol, 16, 153-66. https://doi.org/10.1097/01.mol.0000162320.54795.68
  14. Osman N, O'Leary N, Mulcahy E, et al (2008). Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J, 101, 245-7.
  15. Pan S, Cheng L, White JT, et al (2009). Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS, 13, 345-54. https://doi.org/10.1089/omi.2009.0008
  16. Qiu H, Zhu J, Yu J, Pu H, Dong R (2011). SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated. Asian Pac J Cancer Prev, 12, 791-5.
  17. Sarandakou A, Protonotariou E, Rizos D (2007). Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci, 44, 151-78. https://doi.org/10.1080/10408360601003143
  18. Schumacker PT (2006). Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell, 10, 175-6. https://doi.org/10.1016/j.ccr.2006.08.015
  19. Searle S, Blackwell JM (1999). Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. J Med Genet, 36, 295-9.
  20. Searle S, Bright NA, Roach TI, et al (1998). Localisation of Nramp1 in macrophages: modulation with activation and infection. J Cell Sci, 111, 2855-66.
  21. Whitehouse C, Solomon E (2003). Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol, 88, S152-7. https://doi.org/10.1006/gyno.2002.6708
  22. Wu WW, Wang G, Baek SJ, Shen RF (2006). Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res, 5, 651-8. https://doi.org/10.1021/pr050405o

Cited by

  1. Is Target Oriented Surgery Sufficient with Borderline Ovarian Tumors? - Role of Accompanying Pathologies vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6749
  2. Roles of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios in the Early Diagnosis of Malignant Ovarian Masses vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6881
  3. Circulating Carnosine Dipeptidase 1 Associates with Weight Loss and Poor Prognosis in Gastrointestinal Cancer vol.10, pp.4, 2015, https://doi.org/10.1371/journal.pone.0123566
  4. Analysis of the plasma proteome using iTRAQ and TMT-based Isobaric labeling pp.02777037, 2017, https://doi.org/10.1002/mas.21550
  5. Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine vol.9, pp.7, 2018, https://doi.org/10.3390/genes9070349